Link to article at PubMed

2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.


Metformin, an antidiabetic agent, was approved by the U.S. Food and Drug Administration (FDA) in 1994 for treating type 2 diabetes. This medication comes in both immediate- and extended-release formulations and is often combined with other antidiabetic agents. The off-label indications of metformin include managing gestational diabetes, addressing weight gain issues caused by antipsychotic medication, preventing type 2 diabetes, and treating and preventing polycystic ovary syndrome (PCOS). Metformin is currently the only antidiabetic medication for prediabetes recommended by the American Diabetes Association (ADA). Furthermore, regarding potential indications, researchers are studying metformin for its possible antiaging, anticancer, and neuroprotective effects. This activity offers a comprehensive review of metformin's indications, contraindications, and adverse effects. In addition, it emphasizes the crucial role played by the interprofessional team in effectively managing patients with diabetes.

PMID:30085525 | Bookshelf:NBK518983

Leave a Reply

Your email address will not be published. Required fields are marked *